Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03450629 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Safety and Efficacy of PDP-716
A Phase 3 study of Ocular Hypertension and Open Angle Glaucoma, sponsored by Sun Pharma Advanced Research Company Limited.
- Completed
- Registry status
- Phase 3
- Development phase
- 682
- Enrollment target
- 20
- Study locations
NCT03450629: Completed Phase 3 study of Ocular Hypertension and Open Angle Glaucoma, sponsored by Sun Pharma Advanced Research Company Limited.
NCT03450629 is a Phase 3 study of Ocular Hypertension and Open Angle Glaucoma that has completed, run by Sun Pharma Advanced Research Company Limited. The registered enrollment target is 682 participants, above the 266-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (156% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03450629, a Phase 3 study of Ocular Hypertension and Open Angle Glaucoma, has completed, sponsored by Sun Pharma Advanced Research Company Limited.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 682 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study will be conducted to evaluate the efficacy and safety of topical administration of PDP-716 compared with brimonidine tartrate ophthalmic solution.
Conditions Studied
Interventions
- DRUG Brimonidine Tartrate Ophthalmic Suspension
- DRUG Brimonidine Tartrate Ophthalmic Solution
Study Locations (20)
Florida
- SPARC Site 11 - Coral Springs
- SPARC Site 29 - Deerfield Beach
- SPARC Site 34 - Fort Myers
- SPARC Site 46 - Hollywood
- SPARC Site 21 - Jacksonville
- SPARC Site 35 - Miami
- SPARC Site 27 - Miami
- SPARC Site 10 - Miami
- SPARC Site 16 - Miami
California
- SPARC Site 38 - Burbank
- SPARC Site 44 - Glendale
- SPARC Site 45 - Glendale
- SPARC Site 43 - Mission Hills
- SPARC Site 1 - Newport Beach
- SPARC Site 14 - Santa Barbara
- SPARC Site 47 - Torrance
Arizona
- SPARC Site 4 - Chandler
- SPARC Site 5 - Prescott
- SPARC Site 3 - Sun City
Colorado
- SPARC Site 7 - Colorado Springs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 682 participants |
| Start Date | 2018-09-13 |
| Est. Completion | 2020-12-01 |
| Phase | Phase 3 |
What the finished NCT03450629 record still lists
NCT03450629 is an interventional study that assigns participants to a tested intervention. The registered 682 participants enrollment target is mid-sized for trials with a published cap, above the 266-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (156% higher).
The record links to 2 conditions, with Ocular Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Brimonidine Tartrate Ophthalmic Suspension is the first listed.
NCT03450629 names 20 study sites across 4 states, led by Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT03450629 about?
NCT03450629 is a clinical study titled "Evaluation of Safety and Efficacy of PDP-716". The study will be conducted to evaluate the efficacy and safety of topical administration of PDP-716 compared with brimonidine tartrate ophthalmic solution.
What is the current status of trial NCT03450629?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 682 participants. The study started on 2018-09-13. Estimated completion is 2020-12-01.
What conditions does trial NCT03450629 study?
This clinical trial studies the following conditions: Ocular Hypertension, Open Angle Glaucoma.
What interventions are being tested in trial NCT03450629?
The interventions under investigation include: Brimonidine Tartrate Ophthalmic Suspension (DRUG), Brimonidine Tartrate Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT03450629?
This trial is sponsored by Sun Pharma Advanced Research Company Limited, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03450629 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ocular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03450629's enrollment target sits among peer trials
682 6th of 54 higher than 49 of 54 other Ocular Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ocular Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)
RECRUITING · Phase 3
-
Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Safety and Efficacy Extension Trial of Bimatoprost SR
ACTIVE NOT RECRUITING · Phase 3
-
Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05382559 · 681 participants · Phase 1
A Study of ASP3082 in Adults With Advanced Solid Tumors
- NCT06795087 · 684 participants
Discharge Medication Use Post-Operatively in GU Cancer Patients
- NCT03501706 · 680 participants · NA
An Assessment of Cognitive Improvement Training Among Mid-life Individuals
- NCT05626452 · 680 participants · NA
PrEP Optimization Among Women to Enhance Retention and Uptake
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI